Oncology and Hematology - Prova Education

Episodes 97-112 of 115

Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
MinuteCE®
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
0.75 program credits
- Rana McKay, MD
0.75 program credits
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
MinuteCE®
Guideline Updates for ADT: Best Practices for Treating Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
0.75 program credits
- Tanya Dorff, MD
0.75 program credits
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
MinuteCE®
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
0.75 program credits
- Rana McKay, MD
0.75 program credits
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
MinuteCE®
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
0.75 program credits
- Rana McKay, MD
0.75 program credits
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
MinuteCE®
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
0.75 program credits
- Tanya Dorff, MD
- Rana McKay, MD
0.75 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit

7/7